BioLineRx Cost Of Revenue vs Net Income From Continuing Ops Analysis

BLRX Stock  USD 0.24  0.01  4.00%   
BioLineRx financial indicator trend analysis is way more than just evaluating BioLineRx prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioLineRx is a good investment. Please check the relationship between BioLineRx Cost Of Revenue and its Net Income From Continuing Ops accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Cost Of Revenue vs Net Income From Continuing Ops

Cost Of Revenue vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioLineRx Cost Of Revenue account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have almost no relationship.
The correlation between BioLineRx's Cost Of Revenue and Net Income From Continuing Ops is 0.19. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of BioLineRx, assuming nothing else is changed. The correlation between historical values of BioLineRx's Cost Of Revenue and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of BioLineRx are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Cost Of Revenue i.e., BioLineRx's Cost Of Revenue and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

0.19
Relationship DirectionPositive 
Relationship StrengthInsignificant

Cost Of Revenue

Cost of Revenue is found on BioLineRx income statement and represents the costs associated with goods and services BioLineRx provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Net Income From Continuing Ops

Most indicators from BioLineRx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 22.8 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.05) in 2024.

BioLineRx fundamental ratios Correlations

-0.040.390.67-0.140.56-0.14-0.50.790.660.740.170.410.740.660.650.610.630.650.51-0.740.750.010.830.00.71
-0.040.54-0.420.010.280.60.430.040.39-0.35-0.440.48-0.070.39-0.370.21-0.470.420.04-0.15-0.09-0.24-0.190.380.25
0.390.54-0.380.10.92-0.12-0.280.430.860.19-0.20.970.380.850.310.740.20.790.64-0.810.390.040.230.040.78
0.67-0.42-0.38-0.37-0.19-0.03-0.240.34-0.030.630.4-0.390.31-0.030.36-0.080.430.05-0.01-0.030.32-0.130.71-0.050.02
-0.140.010.1-0.370.150.23-0.030.00.11-0.45-0.20.250.270.14-0.040.17-0.03-0.05-0.28-0.240.250.45-0.34-0.450.37
0.560.280.92-0.190.15-0.24-0.430.610.860.3-0.140.940.630.860.510.870.440.760.7-0.910.650.230.320.020.87
-0.140.6-0.12-0.030.23-0.240.69-0.18-0.13-0.59-0.25-0.14-0.12-0.11-0.37-0.21-0.37-0.09-0.550.28-0.140.06-0.310.12-0.09
-0.50.43-0.28-0.24-0.03-0.430.69-0.43-0.4-0.6-0.14-0.33-0.49-0.4-0.59-0.47-0.6-0.33-0.630.55-0.5-0.18-0.460.18-0.49
0.790.040.430.340.00.61-0.18-0.430.670.41-0.320.520.90.670.460.810.440.650.58-0.760.880.140.450.190.71
0.660.390.86-0.030.110.86-0.13-0.40.670.44-0.210.880.541.00.330.780.260.970.58-0.920.54-0.110.54-0.110.92
0.74-0.350.190.63-0.450.3-0.59-0.60.410.440.480.150.250.430.510.230.490.490.49-0.470.27-0.350.94-0.160.35
0.17-0.44-0.20.4-0.2-0.14-0.25-0.14-0.32-0.210.48-0.25-0.23-0.210.32-0.320.33-0.21-0.060.14-0.19-0.170.45-0.14-0.2
0.410.480.97-0.390.250.94-0.14-0.330.520.880.15-0.250.50.880.340.850.250.770.66-0.870.510.130.190.030.85
0.74-0.070.380.310.270.63-0.12-0.490.90.540.25-0.230.50.550.610.820.610.430.5-0.751.00.480.290.090.74
0.660.390.85-0.030.140.86-0.11-0.40.671.00.43-0.210.880.550.330.790.270.960.57-0.930.55-0.090.53-0.110.93
0.65-0.370.310.36-0.040.51-0.37-0.590.460.330.510.320.340.610.330.540.970.20.58-0.580.650.480.45-0.140.49
0.610.210.74-0.080.170.87-0.21-0.470.810.780.23-0.320.850.820.790.540.50.670.77-0.880.820.330.240.150.84
0.63-0.470.20.43-0.030.44-0.37-0.60.440.260.490.330.250.610.270.970.50.150.52-0.520.650.50.45-0.170.45
0.650.420.790.05-0.050.76-0.09-0.330.650.970.49-0.210.770.430.960.20.670.150.52-0.830.43-0.280.6-0.060.82
0.510.040.64-0.01-0.280.7-0.55-0.630.580.580.49-0.060.660.50.570.580.770.520.52-0.680.520.090.330.250.53
-0.74-0.15-0.81-0.03-0.24-0.910.280.55-0.76-0.92-0.470.14-0.87-0.75-0.93-0.58-0.88-0.52-0.83-0.68-0.75-0.15-0.510.16-0.96
0.75-0.090.390.320.250.65-0.14-0.50.880.540.27-0.190.511.00.550.650.820.650.430.52-0.750.490.320.080.74
0.01-0.240.04-0.130.450.230.06-0.180.14-0.11-0.35-0.170.130.48-0.090.480.330.5-0.280.09-0.150.49-0.36-0.170.19
0.83-0.190.230.71-0.340.32-0.31-0.460.450.540.940.450.190.290.530.450.240.450.60.33-0.510.32-0.36-0.220.47
0.00.380.04-0.05-0.450.020.120.180.19-0.11-0.16-0.140.030.09-0.11-0.140.15-0.17-0.060.250.160.08-0.17-0.22-0.22
0.710.250.780.020.370.87-0.09-0.490.710.920.35-0.20.850.740.930.490.840.450.820.53-0.960.740.190.47-0.22
Click cells to compare fundamentals

BioLineRx Account Relationship Matchups

BioLineRx fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets53.6M47.3M81.4M76.4M63.9M53.7M
Other Current Liab7K1.4M1.2M1.3M3.4M3.5M
Total Current Liabilities12.0M10.6M9.7M10.7M30.9M32.4M
Total Stockholder Equity33.4M22.0M68.1M50.8M13.2M12.6M
Other Liab323K658K10.2M1.9M2.1M2.2M
Accounts Payable7.8M5.9M5.6M7.0M10.9M11.4M
Cash5.3M16.8M13.0M10.6M4.3M8.0M
Long Term Debt7.8M5.8M2.7M8.6M6.6M3.6M
Common Stock Shares Outstanding9.8M16.9M44.2M51.6M64.2M67.4M
Short Term Investments22.2M5.8M44.1M40.5M38.7M28.6M
Other Current Assets108K152K127K198K1.5M1.5M
Total Liab20.2M25.3M13.3M25.5M50.7M53.2M
Intangible Assets21.9M21.7M21.7M21.9M14.9M10.4M
Common Stock4.7M9.9M21.1M27.1M31.4M32.9M
Property Plant Equipment2.2M3.5M2.7M2.3M2.6M2.1M
Short Long Term Debt Total10.5M7.7M4.7M12.3M11.6M12.2M
Property Plant And Equipment Net3.5M2.7M2.3M2.5M1.9M2.2M
Net Debt5.2M(9.1M)(8.3M)1.7M7.3M7.7M
Retained Earnings(248.0M)(278.0M)(305.0M)(330.0M)(390.6M)(371.1M)
Non Current Assets Total25.4M24.4M24.0M24.4M16.7M13.7M
Non Currrent Assets Other56K25.4M21.4M(1.0)(1.15)(1.09)
Cash And Short Term Investments27.5M22.6M57.1M51.1M43.0M39.3M
Net Receivables613K141K142K721K708K430.0K
Common Stock Total Equity2.8M3.1M4.7M9.9M11.4M11.9M
Liabilities And Stockholders Equity53.6M47.3M81.4M76.4M63.9M54.1M
Non Current Liabilities Total8.2M14.6M3.6M14.9M19.9M20.8M
Other Stockholder Equity265.9M279.2M339.3M339.0M355.5M255.4M
Property Plant And Equipment Gross3.5M2.7M6.8M2.5M7.4M7.8M
Total Current Assets28.2M22.9M57.4M52.0M47.2M40.4M
Accumulated Other Comprehensive Income10.7M10.9M11.7M13.3M17.0M10.8M
Short Term Debt2.9M3.3M2.9M2.4M3.7M3.9M
Net Tangible Assets19.3M11.5M316K46.4M41.7M22.1M
Short Long Term Debt2.7M3.1M2.8M1.5M3.1M1.8M
Net Invested Capital41.9M27.9M70.8M61.0M23.0M37.5M
Net Working Capital16.2M12.2M47.7M41.3M16.3M23.2M
Capital Stock4.7M9.9M21.1M27.1M31.4M17.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.